Canadian pharmaceutical company Apotex Inc and Cumberland Pharmaceuticals Inc, a US-based specialty pharmaceutical company, announced on Thursday that they have entered into a strategic transaction to integrate Cumberland's US branded businesses into Apotex.

Under the agreement, Apotex will add a portfolio of branded medicines to its US business. The transaction is expected to significantly expand Apotex's US specialty and hospital focused business with a diversified basket of products across acute care, oncology, infectious disease, and gastroenterology.

The portfolio includes well-established brands such as Kristalose, Caldolor, Sancuso, Vibativ, Acetadote, Vaprisol, and Talicia, which are prescribed across hospitals, oncology, infectious disease, and gastroenterology settings. According to Apotex, these differentiated products benefit from strong clinical data and offer opportunities for continued commercial growth and optimisation under its ownership.

Closing of the transaction is subject to, among other things, the required approval of Cumberland's shareholders.